4342-03-4
4342-03-4
Chemical Structure
Dacarbazine
Synonym(s): Imidazole Carboxamide
- CAS No.: 4342-03-4
- Formula:C6H10N6O
- Molecular Weight:182.18
IUPAC Name: (E)-5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
InChIKey: FDKXTQMXEQVLRF-ZHACJKMWSA-N
SMILES: O=C(C1=C(/N=N/N(C)C)NC=N1)N
Biological Activity: Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC50 of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dacarbazine | 99.96% | Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC50 of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dacarbazine (Standard) | ≥98% | Dacarbazine (Standard) is the analytical standard of Dacarbazine. This product is intended for research and analytical applications. Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC50 of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dacarbazine-d6 | Dacarbazine-d6 is the deuterium labeled Dacarbazine. Dacarbazine(DTIC-Dome; DTIC) is an antineoplastic agent. It has significant activity against melanomas. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Serrone, L., et al., Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res, 2000. 19(1): p. 21-34. [Content Brief]
- [2]. Al-Badr AA, et al. Dacarbazine. Profiles Drug Subst Excip Relat Methodol. 2016;41:323-77. [Content Brief]
- [3]. Rojo JM, et al. Inhibition of T and B lymphoblastic response by mithramycin, dacarbazine, prospidium chloride and peptichemio. Chemotherapy. 1983;29(5):345-51. [Content Brief]
- [4]. Erdmann S, et al. Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment. Sci Rep. 2019 Jan 10;9(1):30. [Content Brief]
- [5]. Salvador D, et al. Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells. Int J Mol Sci. 2022 Mar 25;23(7):3586. [Content Brief]
